JPH06507608A - ベンゾフラン誘導体 - Google Patents

ベンゾフラン誘導体

Info

Publication number
JPH06507608A
JPH06507608A JP4509260A JP50926092A JPH06507608A JP H06507608 A JPH06507608 A JP H06507608A JP 4509260 A JP4509260 A JP 4509260A JP 50926092 A JP50926092 A JP 50926092A JP H06507608 A JPH06507608 A JP H06507608A
Authority
JP
Japan
Prior art keywords
group
methyl
tables
formulas
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4509260A
Other languages
English (en)
Japanese (ja)
Inventor
ロス，バリー　クライブ
ミドルミス，デイビッド
スコープス，デイビッド　イアン　カーター
ジャック，トーキル　イエイン　マックリーン
カードウェル，ケビン　スチュアート
ドウル，マイケル　デニス
ゲーリー モンタナ，ジョン
パス，マーチン
ジュード，ダンカン　ブルース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919110633A external-priority patent/GB9110633D0/en
Priority claimed from GB929201358A external-priority patent/GB9201358D0/en
Priority claimed from GB929205174A external-priority patent/GB9205174D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JPH06507608A publication Critical patent/JPH06507608A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP4509260A 1991-05-16 1992-05-15 ベンゾフラン誘導体 Pending JPH06507608A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB919110633A GB9110633D0 (en) 1991-05-16 1991-05-16 Chemical compounds
GB9110633.6 1991-05-16
GB92013508.0 1992-01-22
GB929201358A GB9201358D0 (en) 1992-01-22 1992-01-22 Chemical compounds
GB9205174.7 1992-03-10
GB929205174A GB9205174D0 (en) 1992-03-10 1992-03-10 Chemical compounds
PCT/GB1992/000887 WO1992020679A1 (en) 1991-05-16 1992-05-15 Benzofuran derivatives

Publications (1)

Publication Number Publication Date
JPH06507608A true JPH06507608A (ja) 1994-09-01

Family

ID=27265657

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4509260A Pending JPH06507608A (ja) 1991-05-16 1992-05-15 ベンゾフラン誘導体

Country Status (15)

Country Link
US (1) US5317023A (enExample)
EP (1) EP0514197A1 (enExample)
JP (1) JPH06507608A (enExample)
KR (1) KR920021542A (enExample)
AU (2) AU654349B2 (enExample)
CA (1) CA2068756A1 (enExample)
CZ (1) CZ242993A3 (enExample)
FI (1) FI935043A0 (enExample)
HU (1) HUT67014A (enExample)
IE (1) IE921569A1 (enExample)
IL (1) IL101888A0 (enExample)
MX (1) MX9202300A (enExample)
NO (1) NO921951L (enExample)
TW (1) TW221997B (enExample)
WO (1) WO1992020679A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022552185A (ja) * 2019-10-09 2022-12-15 バイオクリスト ファーマスーティカルズ，インコーポレイテッド 経口補体因子ｄ阻害剤

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9110636D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
DE4140519A1 (de) * 1991-12-09 1993-06-17 Merck Patent Gmbh Benzofurane
GB9218449D0 (en) 1992-08-29 1992-10-14 Boots Co Plc Therapeutic agents
GB9223860D0 (en) * 1992-11-13 1993-01-06 Glaxo Group Ltd Chemical compounds
GB2279346A (en) * 1993-07-01 1995-01-04 Glaxo Group Ltd Benzofuran intermediates
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
WO2005082904A1 (ja) * 2004-02-26 2005-09-09 Kyowa Hakko Kogyo Co., Ltd. 好中球性炎症疾患の予防及び／または治療剤
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
DE3928177A1 (de) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0400835A1 (en) * 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IE64514B1 (en) * 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
EP0415886A3 (en) * 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
IL95975A (en) * 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
IL96019A0 (en) * 1989-10-31 1991-07-18 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
EP0430300A3 (en) * 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
EP0434038A1 (en) * 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
DE4006693A1 (de) * 1990-03-01 1991-09-05 Schering Ag Neue benzimidazolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
EP0461040A1 (fr) * 1990-06-08 1991-12-11 Roussel Uclaf Dérivés de l'imidazole, leur procédé de préparation, les intermédiaires obtenus, leur application à titre de médicaments et les compositions pharmaceutiques les renfermant
DE4140519A1 (de) * 1991-12-09 1993-06-17 Merck Patent Gmbh Benzofurane

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022552185A (ja) * 2019-10-09 2022-12-15 バイオクリスト ファーマスーティカルズ，インコーポレイテッド 経口補体因子ｄ阻害剤

Also Published As

Publication number Publication date
MX9202300A (es) 1992-11-01
IL101888A0 (en) 1992-12-30
CZ242993A3 (en) 1994-03-16
AU654349B2 (en) 1994-11-03
WO1992020679A1 (en) 1992-11-26
FI935043A7 (fi) 1993-11-15
TW221997B (enExample) 1994-04-01
US5317023A (en) 1994-05-31
CA2068756A1 (en) 1992-11-17
IE921569A1 (en) 1992-11-18
KR920021542A (ko) 1992-12-18
AU1632092A (en) 1993-03-11
EP0514197A1 (en) 1992-11-19
NO921951L (no) 1992-11-17
NO921951D0 (no) 1992-05-15
AU1751192A (en) 1992-12-30
FI935043A0 (fi) 1993-11-15
HUT67014A (en) 1995-01-30
HU9303225D0 (en) 1994-03-28

Similar Documents

Publication Publication Date Title
JPH06507608A (ja) ベンゾフラン誘導体
US4450164A (en) Imidazo[1,2-A]pyridines and use
JP3108483B2 (ja) インドール誘導体およびこれを有効成分とする抗潰瘍薬
CN102036989B (zh) 6-杂芳基咪唑并[1,2-a]吡啶的多取代衍生物及其制备方法和治疗用途
US4464372A (en) Imidazo[1,2-b]pyridazines
CN104718212B (zh) 制备噻吩并嘧啶化合物的方法
CN101268073A (zh) 杂环化合物、制备方法及其用途
US20070149560A1 (en) Novel fused triazolones and the uses thereof
JPH03223281A (ja) ベンゾチオフェン誘導体
JPH01316363A (ja) ピペラジン誘導体およびその塩
JPH06505979A (ja) ベンゾフラン誘導体
US5250531A (en) Dihydropyrimidine antiallergy agents
JP2004512281A (ja) 抗炎症薬として有用なアミノ置換４環化合物および該化合物を含有する医薬組成物
KR20010042307A (ko) 피롤로[1,2-ａ]피라진 ｓＰＬＡ2 억제제
JPH06503083A (ja) ベンゾフラン及びベンゾチオフェン誘導体
US4507294A (en) Imidazo[1,2-a]pyrazines
CN111440146B (zh) 一种具有par4拮抗活性的苯并三嗪类化合物及其应用
JPH03500542A (ja) 新規な化合物及び治療法
CN110903289B (zh) 嘌呤-氨甲基-吡啶酮衍生物及其制备方法和用途
FR2953838A1 (fr) Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique
US6458792B1 (en) Compounds
JP6784942B2 (ja) ４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オン化合物
JP2001507711A (ja) テトラゾリルベンゾピランの製法
JP2686364B2 (ja) セレノフエン誘導体、その製造方法及びセレノフエン誘導体を含む治療組成物
JPH0673052A (ja) ベンゾフラン誘導体